Medical Technologies

Galvanize Therapeutics Raises $130 Million to Scale Pulsed Electric Field Ablation Technology

Galvanize has raised a Series D funding to support the commercialization of its Aliya EX soft tissue ablation platform and develop innovative devices for treating chronic bronchitis using PEF technologies.

2026-11-17
3 min read
10 views
certi.news Editorial Team
Galvanize Therapeutics Raises $130 Million to Scale Pulsed Electric Field Ablation Technology

Galvanize Therapeutics announced the successful completion of a $130 million Series D financing round to accelerate the commercialization of its innovative pulsed electric field (PEF) ablation technology. This step comes just six months after the company received clearance from the U.S. Food and Drug Administration (FDA) for its Aliya EX device, dedicated to the surgical ablation of soft tissue.

Mechanism of Pulsed Electric Field Ablation Technology

Pulsed Electric Field (PEF) technology relies on delivering high-frequency, short-duration energy to induce apoptosis. This method differs from traditional ablation techniques (which often rely on extreme heat or cold) in its ability to precisely destroy targeted cells while preserving the extracellular matrix. This approach significantly reduces collateral damage to healthy tissue or vital structures surrounding the treatment area.

Developing the Aliya Platform and Expanding Treatment Scope

Galvanize secured its first clearance for the Aliya device in 2022, and since then the company has seen significant expansion, including mergers with Gala Therapeutics and Galaxy Medical. The latest version of the device, Aliya EX, provides advanced technical features including:

  • Increased Ablation Zone Diameter: The new system allows physicians to create ablation zones up to 20 mm in diameter, double the diameter provided by the previous version (10 mm).
  • Expanding the Patient Base: The ability to target larger areas makes the device suitable for a broader segment of patients suffering from soft tissue lesions.
  • Higher Surgical Precision: Improvement of the energy generator to ensure the stability of electrical pulses and their direct impact on targeted cells.

Future Horizons: Treating Bronchitis

In addition to soft tissue ablation, the company is allocating part of the new funding to bring the RheOx platform to the U.S. market. This technology, which was already launched in Europe in 2022, uses PEF energy to reduce mucus-producing cells in the lung airways, providing a new therapeutic solution for those with chronic bronchitis.

What Does This News Change in the Medical Sector?

This massive funding represents great confidence in non-thermal ablation technologies. Practically speaking, Galvanize's success in commercializing these devices means providing less invasive and safer alternatives to traditional surgical procedures. Furthermore, moving from small ablation zones to larger ones (20 mm) addresses one of the biggest limitations that early PEF technologies faced, cementing its position as an essential tool in modern operating rooms.

The financing round was led by HealthQuest Capital, with participation from new investors such as Olympus Innovation Ventures and Braidwell, alongside existing investors like Sofinnova Partners and Norwest, reflecting growing interest from major players in the medical technology sector in this type of innovation.

News source
c
Author

certi.news Editorial Team

In the same category

You may also like

View all news